Cite

HARVARD Citation

    Toor, S. et al. (2019). Effect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM‐3+ T cell subsets. Clinical and experimental immunology. pp. 345-352. [Online]. 
  
Back to record